KALA BIO (KALA) Stock Price, News & Analysis

Company Overview

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Key Stats

• Today's Range: $10.39 to $11.68
• 50-Day Range: $4.00 to $11.22
• 52-Week Range: $2.92 to $11.68
• Volume: 404,474 shs
• Average Volume: 135,899 shs
• Market Capitalization: $78.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

KALA BIO Stock Analysis - MarketRank™

KALA BIO scored higher than 69% of companies evaluated by MarketBeat, and ranked 307th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

KALA BIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

KALA BIO has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for KALA BIO are expected to grow in the coming year, from ($10.84) to ($6.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of KALA BIO is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of KALA BIO is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

KALA BIO has a P/B Ratio of 5.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.65% of the float of KALA BIO has been sold short.

Short Interest Ratio / Days to Cover

KALA BIO has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in KALA BIO has recently increased by 8.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

KALA BIO does not currently pay a dividend.

Dividend Growth

KALA BIO does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.35

Percentage of Shares Shorted

6.65% of the float of KALA BIO has been sold short.

Short Interest Ratio / Days to Cover

KALA BIO has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in KALA BIO has recently increased by 8.74%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

KALA BIO has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.11 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for KALA BIO this week, compared to 1 article on an average week.

Search Interest

3 people have searched for KALA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, KALA BIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $162,876.00 in company stock.

Percentage Held by Insiders

Only 8.32% of the stock of KALA BIO is held by insiders.

Percentage Held by Institutions

Only 24.61% of the stock of KALA BIO is held by institutions.

KALA Stock Analysis - Frequently Asked Questions

How have KALA shares performed this year?

KALA BIO's stock was trading at $6.94 on January 1st, 2025. Since then, KALA stock has increased by 61.7% and is now trading at $11.22.

How were KALA BIO's earnings last quarter?

KALA BIO, Inc. (NASDAQ:KALA) announced its earnings results on Friday, August, 8th. The company reported ($1.71) EPS for the quarter, beating analysts' consensus estimates of ($1.82) by $0.11.

When did KALA BIO's stock split?

KALA BIO's stock reverse split on the morning of Friday, October 21st 2022.The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did KALA BIO IPO?

KALA BIO (KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Who are KALA BIO's major shareholders?

Top institutional investors of KALA BIO include AIGH Capital Management LLC (4.65%), OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.97%), Geode Capital Management LLC (0.87%) and Perceptive Advisors LLC (0.79%). Insiders that own company stock include Bros Advisors Lp Baker, Mark T Iwicki, Todd Bazemore, Romulus K Brazzell, Eric Trachtenberg, Darius Kharabi and Mary Reumuth.
View institutional ownership trends.

How do I buy shares of KALA BIO?

Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of KALA BIO own?

Based on aggregate information from My MarketBeat watchlists, some other companies that KALA BIO investors own include Plug Power (PLUG), Ovid Therapeutics (OVID), Fortress Biotech (FBIO), FuelCell Energy (FCEL), Workhorse Group (WKHS), Lipocine (LPCN) and Comtech Telecommunications (CMTL).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 9/01/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KALA
• CIK: 1479419
• Web: www.kalarx.com
• Phone: (781) 996-5252
• Fax: 781-642-0399
• Employees: 30
• Year Founded: 2009

Price Target and Rating

• Average Price Target for KALA BIO: $13.00
• High Price Target: $15.00
• Low Price Target: $12.00
• Potential Upside/Downside: +15.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.51 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -686.43%
• Return on Assets: -76.81%

Debt

• Debt-to-Equity Ratio: 3.19
• Current Ratio: 2.10
• Quick Ratio: 2.10

Sales & Book Value

• Annual Sales: $3.89 million
• Price / Sales: 20.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.02 per share
• Price / Book: 5.55

Miscellaneous

• Outstanding Shares: 7,020,000
• Free Float: 6,437,000
• Market Cap: $78.76 million
• Optionable: Not Optionable
• Beta: -1.82